Broad-spectrum antivirals against viral fusion

Nature Reviews Microbiology

Volumn 13, Issue 7, 2015, Pages 426-437

  Vigant, Frederic ^a   Santos, Nuno C ^b   Lee, Benhur ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CONFORMATIONAL CHANGE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID SPECIFIC ANTIBODY; POLYPEPTIDE ANTIBIOTIC AGENT; RECEPTOR; UNCLASSIFIED DRUG; VIROLYTIC ANTIVIRAL PEPTIDE; VIRUS FUSION INHIBITOR;

CELL MEMBRANE; CONFORMATIONAL TRANSITION; HUMAN; LIPID OXIDATION; MEMBRANE BIOLOGY; MEMBRANE CURVATURE; MEMBRANE FLUIDITY; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; ANIMAL; DRUG EFFECTS; VIROLOGY; VIRUS DISEASES;

HEPATITIS C VIRUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIVIRAL AGENTS; CELL MEMBRANE; HUMANS; MEMBRANE FUSION; VIRUS DISEASES; VIRUS INTERNALIZATION;

EID: 84931576347     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3475     Document Type: Review

References (98)

1. Wolfe, N. D., Dunavan, C. P. & Diamond, J. Origins of major human infectious diseases. Nature 447, 279-283 (2007).
2. Pernet, O. et al. Evidence for henipavirus spillover into human populations in Africa. Nat. Commun. 5, 5342 (2014).
3. Lee, B. & Rota, P. A. (eds) Henipavirus: Ecology, Molecular Virology and Pathogenesis (Springer, 2012).
4. Gatherer, D. The 2014 Ebola virus disease outbreak in West Africa. J. Gen. Virol. 95, 1619-1624 (2014).
5. Chan, J. F. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465-522 (2015).
6. Keesing, F. et al. Impacts of biodiversity on the emergence and transmission of infectious diseases. Nature 468, 647-652 (2010).
7. Preston, N. D., Daszak, P. & Colwell, R. R. The human environment interface: applying ecosystem concepts to health. Curr. Top. Microbiol. Immunol. 365, 83-100 (2013).
8. Anthony, S. J. et al. A strategy to estimate unknown viral diversity in mammals. mBio 4, e00598-13 (2013).
9. Paeshuyse, J., Dallmeier, K. & Neyts, J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr. Opin. Virol. 1, 590-598 (2011).
10. Cosset, F. L. & Lavillette, D. Cell entry of enveloped viruses. Adv. Genet. 73, 121-183 (2011).
11. Yamauchi, Y. & Helenius, A. Virus entry at a glance. J. Cell Sci. 126, 1289-1295 (2013).
12. Plemper, R. K. Cell entry of enveloped viruses. Curr. Opin. Virol. 1, 92-100 (2011).
13. Albertini, A., Bressanelli, S., Lepault, J. & Gaudin, Y. Structure and working of viral fusion machinery. Curr. Top. Membr. 68, 49-80 (2011).
14. White, J. M., Delos, S. E., Brecher, M. & Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 43, 189-219 (2008).
15. Schneck, E., Sedlmeier, F. & Netz, R. R. Hydration repulsion between biomembranes results from an interplay of dehydration and depolarization. Proc. Natl Acad. Sci. USA 109, 14405-14409 (2012).
16. Zhou, Y. & Simmons, G. Development of novel entry inhibitors targeting emerging viruses. Expert Rev. Anti Infect. Ther. 10, 1129-1138 (2012).
17. El Omari, K., Iourin, O., Harlos, K., Grimes, J. M. & Stuart, D. I. Structure of a pestivirus envelope glycoprotein E2 clarifies its role in cell entry. Cell Rep. 3, 30-35 (2013).
18. Li, Y., Wang, J., Kanai, R. & Modis, Y. Crystal structure of glycoprotein E2 from bovine viral diarrhea virus. Proc. Natl Acad. Sci. USA 110, 6805-6810 (2013).
19. Kong, L. et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342, 1090-1094 (2013).
20. Li, Y. & Modis, Y. A novel membrane fusion protein family in Flaviviridae? Trends Microbiol. 22, 176-182 (2014).
21. Mothes, W., Boerger, A. L., Narayan, S., Cunningham, J. M. & Young, J. A. Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell 103, 679-689 (2000).
22. Narayan, S., Barnard, R. J. & Young, J. A. Two retroviral entry pathways distinguished by lipid raft association of the viral receptor and differences in viral infectivity. J. Virol. 77, 1977-1983 (2003).
23. Martens, S. & McMahon, H. T. Mechanisms of membrane fusion: disparate players and common principles. Nat. Rev. Mol. Cell Biol. 9, 543-556 (2008).
24. Markvoort, A. J. & Marrink, S. J. Lipid acrobatics in the membrane fusion arena. Curr. Top. Membr. 68, 259-294 (2011).
25. Zimmerberg, J. & Kozlov, M. M. How proteins produce cellular membrane curvature. Nat. Rev. Mol. Cell Biol. 7, 9-19 (2006).
26. Stachowiak, J. C., Brodsky, F. M. & Miller, E. A. A cost-benefit analysis of the physical mechanisms of membrane curvature. Nat. Cell Biol. 15, 1019-1027 (2013).
27. Henrich, T. J. & Kuritzkes, D. R. HIV-1 entry inhibitors: recent development and clinical use. Curr. Opin. Virol. 3, 51-57 (2013).
28. Ashkenazi, A., Wexler-Cohen, Y. & Shai, Y. Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim. Biophys. Acta 1808, 2352-2358 (2011).
29. Veiga, S., Henriques, S., Santos, N. C. & Castanho, M. Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem. J. 377, 107-110 (2004).
30. Berkhout, B., Eggink, D. & Sanders, R. W. Is there a future for antiviral fusion inhibitors? Curr. Opin. Virol. 2, 50-59 (2012).
31. Liao, M. & Kielian, M. Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J. Cell Biol. 171, 111-120 (2005).
32. Koehler, J. W. et al. A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses. PLoS Negl. Trop. Dis. 7, e2430 (2013).
33. Inoue, T., Moore, P. & Tsai, B. How viruses and toxins disassemble to enter host cells. Annu. Rev. Microbiol. 65, 287-305 (2011).
34. Cook, K. M. & Hogg, P. J. Post-translational control of protein function by disulfide bond cleavage. Antioxid. Redox Signal. 18, 1987-2015 (2013).
35. Wouters, M. A., Lau, K. K. & Hogg, P. J. Cross-strand disulphides in cell entry proteins: poised to act. Bioessays 26, 73-79 (2004).
36. Bi, S., Hong, P. W., Lee, B. & Baum, L. G. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc. Natl Acad. Sci. USA 108, 10650-10655 (2011).
37. Jain, S., McGinnes, L. W. & Morrison, T. G. Role of thiol/disulfide exchange in Newcastle disease virus entry. J. Virol. 83, 241-249 (2009).
38. Stantchev, T. S. et al. Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection. Retrovirology 9, 97 (2012).
39. Fenouillet, E., Barbouche, R. & Jones, I. M. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. Antioxid. Redox Signal. 9, 1009-1034 (2007).
40. Jordan, P. A. & Gibbins, J. M. Extracellular disulfide exchange and the regulation of cellular function. Antioxid. Redox Signal. 8, 312-324 (2006).
41. Garner, O. B. & Baum, L. G. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem. Soc. Trans. 36, 1472-1477 (2008).
42. Elahi, S., Niki, T., Hirashima, M. & Horton, H. Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood 119, 4192-4204 (2012).
43. Hoffstrom, B. G. et al. Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nat. Chem. Biol. 6, 900-906 (2010).
44. Xu, S. et al. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc. Natl Acad. Sci. USA 109, 16348-16353 (2012).
45. Jasuja, R. et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J. Clin. Invest. 122, 2104-2113 (2012).
46. Khan, M. M., Simizu, S., Kawatani, M. & Osada, H. The potential of protein disulfide isomerase as a therapeutic drug target. Oncol. Res. 19, 445-453 (2011).
47. Diwaker, D., Mishra, K. P. & Ganju, L. Potential roles of protein disulphide isomerase in viral infections. Acta Virol. 57, 293-304 (2013).
48. Di Santo, N. & Ehrisman, J. Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose? Cancers 5, 1163-1176 (2013).
49. Muller, J., Naguleswaran, A., Muller, N. & Hemphill, A. Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp. Parasitol. 118, 80-88 (2008).
50. Rossignol, J. F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 110, 94-103 (2014).
51. Keeffe, E. B. & Rossignol, J. F. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J. Gastroenterol. 15, 1805-1808 (2009).
52. Tan, X. et al. Systematic identification of synergistic drug pairs targeting HIV. Nat. Biotechnol. 30, 1125-1130 (2012).
53. Blaising, J., Polyak, S. J. & Pecheur, E. I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 107, 84-94 (2014).
54. Leneva, I. A., Russell, R. J., Boriskin, Y. S. & Hay, A. J. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 81, 132-140 (2009).
55. Haffizulla, J. et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect. Dis. 14, 609-618 (2014).
56. Badani, H., Garry, R. F. & Wimley, W. C. Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. Biochim. Biophys. Acta 1838, 2180-2197 (2014).
57. Jenssen, H., Hamill, P. & Hancock, R. E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511 (2006).
58. Cheng, G. et al. A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 105, 3088-3093 (2008).
59. Sample, C. J. et al. A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses. Peptides 48, 96-105 (2013).
60. Krauson, A. J., He, J. & Wimley, W. C. Determining the mechanism of membrane permeabilizing peptides: identification of potent, equilibrium pore-formers. Biochim. Biophys. Acta 1818, 1625-1632 (2012).
61. Teixeira, V., Feio, M. J. & Bastos, M. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res. 51, 149-177 (2012).
62. Qureshi, A., Thakur, N., Tandon, H. & Kumar, M. AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses. Nucleic Acids Res. 42, D1147-D1153 (2014).
63. Arouri, A. & Mouritsen, O. G. Membrane-perturbing effect of fatty acids and lysolipids. Prog. Lipid Res. 52, 130-140 (2013).
64. Teissier, E. & Pecheur, E. I. Lipids as modulators of membrane fusion mediated by viral fusion proteins. Eur. Biophys. J. 36, 887-899 (2007).
65. Pollock, S. et al. Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J. 24, 1866-1878 (2010).
66. Pollock, S. et al. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc. Natl Acad. Sci. USA 107, 17176-17181 (2010).
67. Ciechonska, M. & Duncan, R. Lysophosphatidylcholine reversibly arrests pore expansion during syncytium formation mediated by diverse viral fusogens. J. Virol. 88, 6528-6531 (2014).
68. St Vincent, M. R. et al. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc. Natl Acad. Sci. USA 107, 17339-17344 (2010).
69. Colpitts, C. C. et al. 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses. J. Virol. 87, 3640-3654 (2013).
70. Melikyan, G. B. Driving a wedge between viral lipids blocks infection. Proc. Natl Acad. Sci. USA 107, 17069-17070 (2010).
71. Vigant, F., Jung, M. & Lee, B. Positive reinforcement for viruses. Chem. Biol. 17, 1049-1051 (2010).
72. Vigant, F. et al. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog. 9, e1003297 (2013).
73. Wolf, M. C. et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl Acad. Sci. USA 107, 3157-3162 (2010).
74. Hollmann, A., Castanho, M. A., Lee, B. & Santos, N. C. Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors. Biochem. J. 459, 161-170 (2014).
75. Watabe, N., Ishida, Y., Ochiai, A., Tokuoka, Y. & Kawashima, N. Oxidation decomposition of unsaturated fatty acids by singlet oxygen in phospholipid bilayer membranes. J. Oleo Sci. 56, 73-80 (2007).
76. Riske, K. A. et al. Giant vesicles under oxidative stress induced by a membrane-anchored photosensitizer. Biophys. J. 97, 1362-1370 (2009).
77. Weber, G. et al. Lipid oxidation induces structural changes in biomimetic membranes. Soft Matter 10, 4241-4247 (2014).
78. Ayuyan, A. G. & Cohen, F. S. Lipid peroxides promote large rafts: effects of excitation of probes in fluorescence microscopy and electrochemical reactions during vesicle formation. Biophys. J. 91, 2172-2183 (2006).
79. Hollmann, A. et al. Effects of singlet oxygen generated by a broad-spectrum viral fusion inhibitor on membrane nanoarchitecture. Nanomedicine 11, 1163-1167 (2015).
80. Vigant, F. et al. The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses. J. Virol. 88, 1849-1853 (2014).
81. Kharkwal, G. B., Sharma, S. K., Huang, Y. Y., Dai, T. & Hamblin, M. R. Photodynamic therapy for infections: clinical applications. Lasers Surg. Med. 43, 755-767 (2011).
82. Idris, N. M. et al. In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat. Med. 18, 1580-1585 (2012).
83. Schutters, K. & Reutelingsperger, C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis 15, 1072-1082 (2010).
84. Soares, M. M., King, S. W. & Thorpe, P. E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 14, 1357-1362 (2008).
85. Schoggins, J. W. & Randall, G. Lipids in innate antiviral defense. Cell Host Microbe 14, 379-385 (2013).
86. van Meer, G. & de Kroon, A. I. Lipid map of the mammalian cell. J. Cell Sci. 124, 5-8 (2011).
87. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 1, 13-25 (2002).
88. Forum on Medical and Public Health Preparedness for Catastrophic Events, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine. Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary (National Academies Press, 2011).
89. Murphy, S. V. & Atala, A. 3D bioprinting of tissues and organs. Nat. Biotechnol. 32, 773-785 (2014).
90. Bhatia, S. N. & Ingber, D. E. Microfluidic organs-on-chips. Nat. Biotechnol. 32, 760-772 (2014).
91. Samson, M., Pizzorno, A., Abed, Y. & Boivin, G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 98, 174-185 (2013).
92. Moss, R. B. et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J. Infect. Dis. 206, 1844-1851 (2012).
93. Chalkias, S. et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl. Infect. Dis. 16, 141-144 (2014).
94. Wisskirchen, K., Lucifora, J., Michler, T. & Protzer, U. New pharmacological strategies to fight enveloped viruses. Trends Pharmacol. Sci. 35, 470-478 (2014).
95. Mercer, J., Schelhaas, M. & Helenius, A. Virus entry by endocytosis. Annu. Rev. Biochem. 79, 803-833 (2010).
96. Gillespie, E. J. et al. Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc. Natl Acad. Sci. USA 110, E4904-E4912 (2013).
97. Morizono, K. & Chen, I. S. Role of phosphatidylserine receptors in enveloped virus infection. J. Virol. 88, 4275-4290 (2014).
98. Spence, J. S., Melnik, L. I., Badani, H., Wimley, W. C. & Garry, R. F. Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism. J. Virol. 88, 8556-8564 (2014).